LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

BALLERUP, Denmark I May 09, 2025 I LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline results of the phase 2b trial with ...

LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline results of the phase 2b trial with temtokibart, an investigational IL-22RA1 antagonist, for the potential ...

according to the second phase of the survey sponsored by LEO Pharma Inc., a global leader in medical dermatology, and conducted by Ipsos. The survey, which includes responses from 100 doctors and ...

LEO Pharma and the Parker Institute at Copenhagen University Hospital have entered into a three-year academic partnership aimed at advancing dermatology research. The alliance will focus on enhancing ...

To learn more about CHE, visit www.TalkCHE.com. LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with ...

Delgocitinib is under investigation in Canada and the United States. LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of ...

according to the second phase of the survey sponsored by LEO Pharma Inc., a global leader in medical dermatology, and conducted by Ipsos.

[email protected] LEO Pharma A/S, a global leader in medical dermatology, is pleased to share that The Lancet, which is considered one of the most influential peer-reviewed medical journals in ...